Cpg 684: An Effective Adjuvant for the Inactivated COVID-19 Vaccine in Mice

References

• Mistry P , BarmaniaF , MelletJet al. SARS-CoV-2 variants, vaccines, and host immunity. Front. Immunol.12, 809244 (2021).
   PubMed Web of Science ®Google Scholar
• Team CC-R . SARS-CoV-2 B.1.1.529 (Omicron) variant – United States, December 1–8, 2021. Morb. Mortal. Wkly Rep.70, 1731–1734 (2021).
   PubMed Web of Science ®Google Scholar
• Potdar V , VipatV , JadhavSet al. Detection of SARS-CoV-2 variants in India from UK returnees. Infection49, 1355–1359 (2021).
   PubMed Web of Science ®Google Scholar
• Adiga R , NayakV. Emergence of novel SARS-CoV-2 variants in India: second wave. J. Infect. Dev. Ctries.15, 1578–1583 (2021).
   PubMed Web of Science ®Google Scholar
• Baden LR , ElSahly HM , EssinkBet al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med.384, 403–416 (2021).
   PubMed Web of Science ®Google Scholar
• Polack FP , ThomasSJ , KitchinNet al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med.383, 2603–2615 (2020).
   PubMed Web of Science ®Google Scholar
• Tanriover MD , DoganayHL , AkovaMet al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase III trial in Turkey. Lancet398, 213–222 (2020).
   Web of Science ®Google Scholar
• Logunov DY , DolzhikovaIV , ShcheblyakovDVet al. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled Phase III trial in Russia. Lancet397, 671–681 (2021).
   PubMed Web of Science ®Google Scholar
• Falsey AR , SobieszczykME , HirschIet al. Phase III safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine. N. Engl. J. Med.385, 2348–2360 (2021).
   PubMed Web of Science ®Google Scholar
• Sadoff J , GrayG , VandeboschAet al. 2021 safety and efficacy of single-dose Ad26.COV2.S vaccine against COVID-19. N. Engl. J. Med.384, 2187–2201 (2021).
   PubMed Web of Science ®Google Scholar
• Bian L , GaoF , ZhangJet al. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. Expert Rev. Vaccines20, 365–373 (2021).
   PubMed Web of Science ®Google Scholar
• Ikegame S , SiddiqueyMNA , HungCTet al. Neutralizing activity of sputnik V vaccine sera against SARS-CoV-2 variants. Nat. Commun.12, 4598 (2021).
   PubMed Web of Science ®Google Scholar
• Sharun K , TiwariR , DhamaKet al. Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies. Hum. Vaccin. Immunother.17, 3491–3494 (2021).
   PubMed Web of Science ®Google Scholar
• Bode C , ZhaoG , SteinhagenFet al. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines10, 499–511 (2011).
   PubMed Web of Science ®Google Scholar
• King K , LarsenBB , GryseelsSet al. Coevolutionary analysis implicates toll-like receptor 9 in papillomavirus restriction. mBio13, e0005422 (2022).
   PubMed Web of Science ®Google Scholar
• Yi AK , ChangM , PeckhamDWet al. CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. J. Immunol.160, 5898–5906 (1998).
   PubMed Web of Science ®Google Scholar
• Davis HL , WeeratnaR , WaldschmidtTJet al. 1998 CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol.160, 870–876 (1998).
   PubMed Web of Science ®Google Scholar
• Liu N , OhnishiN , NiLet al. CpG directly induces T-bet expression and inhibits IgG1 and IgE switching in B cells. Nat. Immunol.4, 687–693 (2003).
   PubMed Web of Science ®Google Scholar
• He B , QiaoX , CeruttiA. CpG DNA induces IgG class switch DNA recombination by activating human B cells through an innate pathway that requires TLR9 and cooperates with IL-10. J. Immunol.173, 4479–4491 (2004).
   PubMed Web of Science ®Google Scholar
• Hartmann G , WeinerGJ , KriegAM. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl Acad. Sci. USA96, 9305–9310 (1999).
   PubMed Web of Science ®Google Scholar
• FDA . Vaccines-blood-biologics/vaccines/heplisav-b. https://www.fda.gov/vaccines-blood-biologics/vaccines/heplisav-b
   Google Scholar
• Liu L , ShenL , LiuXet al. 2012 A safety study of a B-class CpG ODN in Sprague-Dawley rats. J. Appl. Toxico.32, 60–71 (2012).
   PubMed Web of Science ®Google Scholar
• Gursel M , VerthelyiD , KlinmanDM. CpG oligodeoxynucleotides induce human monocytes to mature into functional dendritic cells. Eur. J. Immunol.32, 2617–2622 (2002).
   PubMed Web of Science ®Google Scholar
• Heger E , SchuetzA , VasanS. HIV vaccine efficacy trials: RV144 and beyond. Adv. Exp. Med. Biol.1075, 3–30 (2018).
   PubMed Web of Science ®Google Scholar
• Azkur AK , AkdisM , AzkurDet al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy75(7), 1564–1581 (2020).
   PubMed Web of Science ®Google Scholar
• Romagnani S . T-cell subsets (Th1 versus Th2). Ann. Allergy Asthma Immunol.85, 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Romagnani S . Th1/Th2 cells. Inflamm. Bowel Dis.5, 285–294 (1999).
   PubMed Web of Science ®Google Scholar
• Infante-Duarte C , KamradtT. Th1/Th2 balance in infection. Springer Semin. Immunopathol.21, 317–338 (1999).
   PubMed Web of Science ®Google Scholar
• Kidd P . Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev.8, 223–246 (2003).
   PubMedGoogle Scholar
• Yang L , LianZ , ZhangBet al. Effect of ligustrazine nanoparticles on Th1/Th2 balance by TLR4/MyD88/NF-kappaB pathway in rats with postoperative peritoneal adhesion. BMC Surg.21, 211 (2021).
   PubMed Web of Science ®Google Scholar
• Yamaguchi K , HisanoM , IsojimaSet al. Relationship of Th1/Th2 cell balance with the immune response to influenza vaccine during pregnancy. J. Med. Virol.81, 1923–1928 (2000).
   Google Scholar
• Pacheco IL , AbrilN , Morales-PrietoNet al. Th1/Th2 balance in the liver and hepatic lymph nodes of vaccinated and unvaccinated sheep during acute stages of infection with Fasciola hepatica. Vet. Parasitol.238, 61–65 (2017).
   PubMed Web of Science ®Google Scholar
• Kuo T-Y , LinM-Y , CoffmanRLet al. Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19. Sci. Rep.10(1), 20085 (2020).
   PubMed Web of Science ®Google Scholar